TD Cannabase Gel Kit

Cannabase gel kit enables the incorporation of Phytoceuticals and essential oils during the formulation process which will result in a more stable finished product and enhanced transdermal delivery of active ingredients. With the versatile Cannabase gel kit, the finished product can be customized to meet the unique compounding needs of the patients, yet is conveniently packed for ease of preparation.

This base can be used as a Transdermal delivery system for Cannabinoid molecules ¹ and other lipophilic phytoceuticals with synergistic anti-inflammatory and analgesic effect in the management of difficult to treat pain ^2-5.

PLO Kit Highlighted Benefits

• Easy to incorporate active ingredients
• Compatible with terpenes and essential oils
• Deep dermal penetration
• It allows the formulator to incorporate multiple active ingredients with high concentration
• It can be used for Phytoceuticals, essential oils and extracts.
• Heat is not required to dissolve the active ingredients
• Natural emulsifier
• Paraben free
• Improved stability

Compounding Procedure

1. Levigate the active ingredients in powder form using a wetting agent such as Ethoxy Diglycol. Essential oils or terpenes can be used as levigating agent as well.  
2. Add Organic phase and mix until uniformly dispersed or dissolved.
3. Add Hydrophilic phase by geometrical method to the mix of A and B. Mix well until a homogenous gel is formed.

Compounding Tips

• Store Organic phase at room temperature, and Hydrophilic phase in the refrigerator. NOTE: Hydrophilic is made of a thermoreversible polymer. It is solid at room temperature, and liquefies at refrigerated temperature.
• Warm Hydrophilic phase to about 10°C prior to compounding to improve the rate of the gelling process.
• Complete dispersion or dissolution of isolate/distillate in Organic phase is important before incorporating Hydrophilic in order to obtain best results.

References 

1. Bruni N1, Della Pepa C2, Oliaro-Bosso S3, Pessione E4, Gastaldi D5, Dosio F6., Cannabinoid Delivery Systems for Pain and Inflammation Treatment,  Molecules. 2018 Sep 27;23(10).

2. Manzanares J, Julian M, Carrascosa A., Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol. 2006 Jul;4(3):239-57.

3. Russo E, Cannabinoids in the management of difficult to treat pain, Ther Clin Risk Manag. 2008 Feb; 4(1): 245–259.

4. Guindon J, De Léan A, Beaulieu P. Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. Pain. 2006 Mar;121(1-2):85-93. Epub 2006 Feb 9.

5. https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/information-medical-practitioners/information-health-care-professionals-cannabis-cannabinoids.html#a2.2.1.6

Disclaimer: Transderma Pharmaceuticals Inc. has provided the formula and instructions above as a model for educational purposes only on the basis of recognized compendia and texts or references. Transderma Pharmaceuticals Inc. takes no responsibility for the validity or accuracy of this information or for its safety or effectiveness, nor for any use thereof, which is at the sole risk of the licensed pharmacist. Adjustments may be needed to meet specific patient needs and in accordance with a licensed prescriber’s prescription. The pharmacist must employ appropriate tests to determine the stability of this suggested formula. Transderma Pharmaceuticals Inc., its owners, officers, agents, contractors, affiliates and employees cannot be held liable to any person or entity concerning claims, loss or damage caused by, or alleged to be caused by, directly or indirectly, the use or misuse of the information contained in this suggested formula. In all cases, it is the responsibility of the licensed pharmacist to know the law, to compound any finished product and to dispense these products in accordance with Health Canada and FDA guidelines and appropriate Provincial Drug Schedules and Provincial or Territorial Pharmacy Practice Standards.